Status:
TERMINATED
The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Constipation Predominant
Irritable Bowel Syndrome (IBS-C)
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.
Eligibility Criteria
Inclusion
- Female 18 and older
- IBS-C patients diagnosed on the basis of Rome II criteria
- Ability to comply with the requirements of the entire study
Exclusion
- Evidence of structural abnormality of the gastrointestinal tract or disease/conditions.
- Patients with previous gastrointestinal surgery other than appendectomy or cholecystectomy.
- Evidence of cathartic colon or a history of laxative use, that in the investigator's opinion is consistent with severe laxative dependence such that the patient is likely to require or use laxatives during the study
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00171431
Start Date
November 1 2004
End Date
May 1 2006
Last Update
April 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048